Daiichi-Sankyo Slashing 1,000+ US Jobs Ahead Of Benicar Expiry
This article was originally published in PharmAsia News
Executive Summary
Japanese major Daiichi-Sankyo is preparing to cut up to 1,200 mainly sales positions in the US ahead of the loss of exclusivity for blockbuster antihypertensive Benicar, and amid a shift in its business model away from primary care and toward specialty products.
You may also be interested in...
Daiichi Closing Indian Site As Global Restructuring Continues
Daiichi Sankyo's decision to close an R&D facility in India has drawn mixed responses from the local industry, coming as it does against the backdrop of the Japanese firm’s disastrous acquisition of Ranbaxy.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.